1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Oxamnique Oral Suspension
Trade Name: MANSIL; VANSIL
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as Antihelmintic

Details of the Supplier of the Safety Data Sheet
Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification
Acute Oral Toxicity: Category 4

EU Classification:
EU Indication of danger: Harmful
EU Risk Phrases:
R22 - Harmful if swallowed.

Label Elements
Signal Word: Warning
Hazard Statements:
H302 - Harmful if swallowed

Precautionary Statements:
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell
P330 - Rinse mouth
P501 - Dispose of contents/container in accordance with all local and national regulations
SAFETY DATA SHEET

Material Name: Oxamniquine Oral Suspension
Revision date: 12-Apr-2015

Other Hazards
Australian Hazard Classification (NOHSC):
No data available

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxamniquine</td>
<td>21738-42-1</td>
<td>244-556-4</td>
<td>T;R25</td>
<td>Acute Tox.2 (H300)</td>
<td>5</td>
</tr>
<tr>
<td>Glycerol</td>
<td>56-81-5</td>
<td>200-289-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agar</td>
<td>9002-18-0</td>
<td>232-658-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Flavoring</td>
<td>NOT ASSIGNED</td>
<td></td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium saccharin</td>
<td>128-44-9</td>
<td>204-886-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>200-334-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sorbitol solution</td>
<td>50-70-4</td>
<td>200-061-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>9005-65-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Purified water</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures
Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. Remove contaminated clothing and shoes. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.
SAFETY DATA SHEET

Material Name: Oxamniquine Oral Suspension
Revision date: 12-Apr-2015

Ingestion: Get medical attention immediately. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. Get medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products:
Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

Fire / Explosion Hazards: Not determined

Advice for Fire-Fighters
Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Incompatible Materials: None identified

Specific end use(s): Pharmaceutical product
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

SODIUM CHLORIDE
- Latvia OEL - TWA: 5 mg/m³
- Lithuania OEL - TWA: 5 mg/m³

Glycerol
- Australia TWA: 10 mg/m³
- Belgium OEL - TWA: 10 mg/m³
- Czech Republic OEL - TWA: 10 mg/m³
- Estonia OEL - TWA: 10 mg/m³
- Finland OEL - TWA: 20 mg/m³
- France OEL - TWA: 10 mg/m³
- Germany (DFG) - MAK: 50 mg/m³
- Greece OEL - TWA: 10 mg/m³
- Ireland OEL - TWAs: 10 mg/m³
- OSHA - Final PELS - TWAs: 15 mg/m³
- Poland OEL - TWA: 10 mg/m³
- Portugal OEL - TWA: 10 mg/m³
- Spain OEL - TWA: 10 mg/m³
- Switzerland OEL - TWAs: 50 mg/m³

Sucrose
- ACGIH Threshold Limit Value (TWA): 10 mg/m³
- Australia TWA: 10 mg/m³
- Belgium OEL - TWA: 10 mg/m³
- Bulgaria OEL - TWA: 10.0 mg/m³
- Estonia OEL - TWA: 10 mg/m³
- France OEL - TWA: 10 mg/m³
- Ireland OEL - TWAs: 10 mg/m³
- Latvia OEL - TWA: 5 mg/m³
- Lithuania OEL - TWA: 10 mg/m³
- OSHA - Final PELS - TWAs: 15 mg/m³
- Portugal OEL - TWA: 10 mg/m³
- Slovakia OEL - TWA: 6 mg/m³
- Spain OEL - TWA: 10 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Oxamniquine
Pfizer Occupational Exposure Band (OEB): OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Exposure Controls
Engineering Controls:
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section.
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:**
Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:**
Wear safety glasses or goggles if eye contact is possible.

**Skin:**
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:**
Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Physical State:
**Suspension**

**Odor:**
No data available.

**Molecular Formula:**
Mixture

**Color:**
Yellow

**Odor Threshold:**
No data available.

**Molecular Weight:**
Mixture

**Solvent Solubility:**
No data available

**Water Solubility:**
No data available

**pH:**
7.0-9.0

**Melting/Freezing Point (°C):**
No data available

**Boiling Point (°C):**
No data available.

**Partition Coefficient:** (Method, pH, Endpoint, Value)

**Oxamniquine**
No data available

**Agar**
No data available

**Sorbitol solution**
No data available

**Sodium saccharin**
No data available

**SODIUM CHLORIDE**
No data available

**Polysorbate 80**
No data available

**Glycerol**
No data available

**Flavoring**
No data available

**Sucrose**
No data available

**Purified water**
No data available

**Decomposition Temperature (°C):**
No data available.

**Evaporation Rate (Gram/s):**
No data available

**Vapor Pressure (kPa):**
No data available

**Vapor Density (g/ml):**
No data available

**Relative Density:**
No data available

**Viscosity:**
No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):**
No data available

**Flammability (Solids):**
No data available
10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions

Oxidizing Properties: No data available
Conditions to Avoid: None known
Incompatible Materials: None identified
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: Not a skin irritant; Not an eye irritant (based on components).
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on kidneys, liver, lungs, blood, central nervous system.
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including dizziness, drowsiness, headache, stomach pain, nausea, vomiting, diarrhea, loss of appetite and red discoloration of the urine. Fever, hallucination, excitement, skin rashes, insomnia, joint pain, temporary amnesia, chills and seizures, especially in persons with a history of epilepsy, have also been reported.

Acute Toxicity: (Species, Route, End Point, Dose)

**Oxamniquine**
- Rat Oral LD50 30 mg/kg
- Mouse Oral LD50 1300mg/kg
- Rat IM LD50 60mg/kg
- Mouse IM LD50 2000mg/kg
- Rat IP LD50 20mg/kg

**Sorbitol solution**
- Rat Oral LD50 15,900 mg/kg
- Mouse Oral LD50 17,800mg/kg

**Sodium saccharin**
- Mouse Oral LD50 17.5 g/kg
- Rat Oral LD50 14.2 - 17g/kg
- Rat Intraperitoneal LD50 7100mg/kg

**SODIUM CHLORIDE**
- Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
- Rat Oral LD 50 3g/kg
- Mouse Oral LD 50 4g/kg
- Rabbit Dermal LD 50 > 10g/kg
11. TOXICOLOGICAL INFORMATION

### Polysorbate 80
- **Species:** Rat  **Route:** Oral  **Duration:** LD50  **Dose:** 25 g/kg

### Glycerol
- **Species:** Rat  **Route:** Oral  **Duration:** LD 50  **Dose:** 12600 mg/kg

### Sucrose
- **Species:** Rat  **Route:** Oral  **Duration:** LD50  **Dose:** 29.7 g/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

### Irritation / Sensitization: (Study Type, Species, Severity)

#### SODIUM CHLORIDE
- **Study:** Skin Irritation  **Species:** Rabbit  **Severity:** Mild
- **Study:** Eye Irritation  **Species:** Rabbit  **Severity:** Mild

#### Glycerol
- **Study:** Skin Irritation  **Species:** Rabbit  **Severity:** Mild
- **Study:** Eye Irritation  **Species:** Rabbit  **Severity:** Mild

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Oxamniquine
- **4 Week(s):** Mouse  **Route:** Oral  **Dose:** 120 mg/kg  **NOAEL:** Blood, Central nervous system, Kidney, Liver, Lungs
- **4 Week(s):** Dog  **Route:** Oral  **Dose:** 20 mg/kg/day  **NOAEL:** Central Nervous System, Kidney, Liver, Lungs
- **11 Month(s):** Dog  **Route:** Oral  **Dose:** 20 mg/kg/day  **LOAEL:** Central Nervous System
- **13 Month(s):** Dog  **Route:** Intramuscular  **Dose:** 30 mg/kg  **NOAEL:** No effects at maximum dose
- **14 Month(s):** Dog  **Route:** Oral  **Dose:** 30 mg/kg  **LOAEL:** Central Nervous System

#### Sodium saccharin
- **36 Week(s):** Rat  **Route:** Oral  **Dose:** 756 g/kg  **LOAEL:** Kidney, Ureter, Bladder
- **54 Day(s):** Rat  **Route:** Oral  **Dose:** 32400 mg/kg  **LOAEL:** Immune system

#### Glycerol
- **28 Day(s):** Rat  **Route:** Oral  **Dose:** 16800 mg/kg  **LOAEL:** Endocrine system

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### Oxamniquine
- **Reproductive & Fertility:** Mouse  **Route:** Intramuscular  **Dose:** 300 mg/kg  **LOAEL:** Fetotoxicity
- **Embryo / Fetal Development:** Mouse  **Route:** Oral  **Dose:** 200 mg/kg/day  **NOAEL:** Fetotoxicity
- **Embryo / Fetal Development:** Mouse  **Route:** Intramuscular  **Dose:** 300 mg/kg/day  **NOAEL:** Negative
- **Embryo / Fetal Development:** Rabbit  **Route:** Oral  **Dose:** 300 mg/kg/day  **NOAEL:** Negative
- **Embryo / Fetal Development:** Rabbit  **Route:** Intramuscular  **Dose:** 400 mg/kg  **NOAEL:** Negative

#### Glycerol
- **Reproductive & Fertility-Males:** Rat  **Route:** Oral  **Dose:** 100 mg/kg  **LOEL:** Fertility
11. TOXICOLOGICAL INFORMATION

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Oxamnique
Bacterial Mutagenicity (Ames)  *Salmonella, E. coli*  Positive
Direct DNA Damage  Bacteria  Negative
*In Vitro*  Human Lymphocytes  Negative
*In Vivo*  Mouse Bone Marrow  Negative
Dominant Lethal Assay  Not specified  Negative

Sucrose
Bacterial Mutagenicity (Ames)  *Salmonella*  Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Oxamnique
18 Month(s)  Mouse  Oral  150 mg/kg  NOAEL  Not carcinogenic
19 Month(s)  Hamster  Intramuscular  150 mg/kg  NOAEL  Not carcinogenic

Carcinogen Status:  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Sodium saccharin
IARC:  Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:  Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:  No data available

Persistence and Degradability:  No data available

Bio-accumulative Potential:  No data available

Mobility in Soil:  No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:  Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.
Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Non-controlled
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Oxamniquine
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
EU EINECS/ELINCS List 244-556-4

Agar
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 232-658-1

SODIUM CHLORIDE
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 231-598-3

Flavoring
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
EU EINECS/ELINCS List Not Listed

Glycerol
## 15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material Name: Oxamniquine Oral Suspension</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CERCLA/SARA 313 Emission reporting</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>California Proposition 65</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>Inventory - United States TSCA - Sect. 8(b)</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>Australia (AICS):</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>REACH - Annex V - Exemptions from the obligations of Register:</strong></td>
<td>Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern</td>
</tr>
<tr>
<td><strong>EU EINECS/ELINCS List</strong></td>
<td>200-289-5</td>
</tr>
<tr>
<td><strong>Sodium saccharin</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CERCLA/SARA 313 Emission reporting</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>California Proposition 65</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>Inventory - United States TSCA - Sect. 8(b)</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>Australia (AICS):</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>EU EINECS/ELINCS List</strong></td>
<td>204-886-1</td>
</tr>
<tr>
<td><strong>Sucrose</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CERCLA/SARA 313 Emission reporting</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>California Proposition 65</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>Inventory - United States TSCA - Sect. 8(b)</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>Australia (AICS):</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>REACH - Annex IV - Exemptions from the obligations of Register:</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>EU EINECS/ELINCS List</strong></td>
<td>200-334-9</td>
</tr>
<tr>
<td><strong>Sorbitol solution</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CERCLA/SARA 313 Emission reporting</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>California Proposition 65</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>Inventory - United States TSCA - Sect. 8(b)</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>Australia (AICS):</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>REACH - Annex IV - Exemptions from the obligations of Register:</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>EU EINECS/ELINCS List</strong></td>
<td>200-061-5</td>
</tr>
<tr>
<td><strong>Polysorbate 80</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CERCLA/SARA 313 Emission reporting</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>California Proposition 65</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>Inventory - United States TSCA - Sect. 8(b)</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>Australia (AICS):</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>EU EINECS/ELINCS List</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>Purified water</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CERCLA/SARA 313 Emission reporting</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>California Proposition 65</strong></td>
<td>Not Listed</td>
</tr>
<tr>
<td><strong>Inventory - United States TSCA - Sect. 8(b)</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>Australia (AICS):</strong></td>
<td>Present</td>
</tr>
</tbody>
</table>

MAŃSIL ORAL SUSPENSION
15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List 231-791-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3
Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed

T - Toxic
R25 - Toxic if swallowed.

Data Sources: Safety data sheets for individual ingredients. Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.

Revision date: 12-Apr-2015

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet